Cargando…

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis

BACKGROUND: Serious mental illnesses are associated with increased risk of cardiometabolic comorbidities. The objective of this study was to evaluate the prevalence of cardiometabolic comorbidity and its association with hospitalization outcomes and costs among inpatients with schizophrenia or bipol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correll, Christoph U., Ng-Mak, Daisy S., Stafkey-Mailey, Dana, Farrelly, Eileen, Rajagopalan, Krithika, Loebel, Antony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301338/ https://www.ncbi.nlm.nih.gov/pubmed/28203265 http://dx.doi.org/10.1186/s12991-017-0133-7

Ejemplares similares

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records
por: Meyer, Jonathan M., et al.
Publicado: (2017)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
por: Newcomer, John W., et al.
Publicado: (2018)

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
por: Raju, Aditya, et al.
Publicado: (2021)

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
por: Awad, George, et al.
Publicado: (2016)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis
por: Arango, Celso, et al.
Publicado: (2019)

The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment
por: Ng-Mak, Daisy, et al.
Publicado: (2017)

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
por: Awad, George, et al.
Publicado: (2014)

The clinical-familial correlates and naturalistic outcome of panic-disorder-agoraphobia with and without lifetime bipolar II comorbidity
por: Toni, Cristina, et al.
Publicado: (2008)

Hysterectomy for benign conditions: Complications relative to surgical approach and other variables that lead to post-operative readmission within 90 days of surgery
por: Lonky, Neal M, et al.
Publicado: (2017)

Effects of comorbid alcohol use disorder on the clinical outcomes of first-episode schizophrenia: a nationwide population-based study
por: Ahn, Soojin, et al.
Publicado: (2021)

Poorer sustained attention in bipolar I than bipolar II disorder
por: Kung, Chian-Huei, et al.
Publicado: (2010)

Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire
por: Montejo, Angel L, et al.
Publicado: (2011)

A survey of caregiver burden in those providing informal care for patients with schizophrenia or bipolar disorder with agitation: results from a European study
por: Blanthorn-Hazell, Sophee, et al.
Publicado: (2018)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Obsessive–compulsive disorder comorbid with schizophrenia and bipolar disorder
por: Sharma, Lavanya P., et al.
Publicado: (2019)

Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression
por: Datto, Catherine, et al.
Publicado: (2016)

Shared genetic underpinnings of childhood obesity and adult cardiometabolic diseases
por: Tekola-Ayele, Fasil, et al.
Publicado: (2019)

Readmission Rates in Schizophrenia and Bipolar Affective Disorder-A Retrospective Chart Analysis Study
por: Fathima.M, Nasreen, et al.
Publicado: (2022)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
por: Kim, Hye Ok, et al.
Publicado: (2020)

Efficacy of the interpersonal and social rhythm therapy (IPSRT) in patients with bipolar disorder: results from a real-world, controlled trial
por: Steardo, Luca, et al.
Publicado: (2020)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Lower paraoxonase 1 activity in Tunisian bipolar I patients
por: Ezzaher, Asma, et al.
Publicado: (2010)

The neurocognitive functioning in bipolar disorder: a systematic review of data
por: Tsitsipa, Eirini, et al.
Publicado: (2015)

PS37. Lurasidone in the Treatment of Bipolar Depression: Effect of Baseline Depression Severity on Clinical Outcome
por: Pikalov, Andrei, et al.
Publicado: (2016)

Cognitive impairment in manic bipolar patients: important, understated, significant aspects
por: Vrabie, Mădălina, et al.
Publicado: (2015)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Mediation model of comorbid anxiety disorders in late-life depression
por: Suradom, Chawisa, et al.
Publicado: (2020)

Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry
por: Maremmani, Icro, et al.
Publicado: (2012)

Leveling and abuse among patients with bipolar disorder at psychiatric outpatient departments in Ethiopia
por: Belete, Habte
Publicado: (2017)

White matter abnormalities of corpus callosum in patients with bipolar disorder and suicidal ideation
por: Zhang, Ran, et al.
Publicado: (2019)

Physical anhedonia in the acute phase of schizophrenia
por: Kontaxakis, Vassilis P, et al.
Publicado: (2006)

A Shoulder Health Survey: Correlating Behaviors and Comorbidities With Shoulder Problems
por: Kane, Steven, et al.
Publicado: (2010)

Anhedonia in schizophrenia and major depression: state or trait?
por: Pelizza, Lorenzo, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lqa32dh9mll02gaattt2thon4i